Clinical Trial

Multiparametric MR-Guided High Dose Adaptive Radiotherapy With Concurrent Temozolomide in Patients With Newly Diagnosed Glioblastoma

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study will investigate whether or not intensified radiation therapy adapted during the radiation treatment course to high-risk, treatment-resistant tumor regions will improve overall survival in patients with newly diagnosed glioblastoma (GBM) compared to conventional chemoradiotherapy.
Protocol Amendment History 9 amendments
This ClinicalTrials.gov record has been amended 9 times since 2020-09-28; most recent amendment 2026-03-24.
Status change: Recruiting → Active, Not Recruiting 2025-10-14
Status change: Not Yet Recruiting → Recruiting 2021-01-10
Trial Details
NCT Number NCT04574856
Lead Sponsor University of Michigan Rogel Cancer Center
Conditions Glioblastoma
Enrollment 30 participants
Start Date 2020-11-04
Primary Completion 2026-11-19 (estimated)
Study Completion 2027-11-19 (estimated)
Updated on ClinicalTrials.gov 2026-03-25